$234 Million is the total value of Ghost Tree Capital, LLC's 35 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BIIB | Exit | BIOGEN INC | $0 | – | -3,750 | -100.0% | -0.28% | – |
| ISEE | Exit | IVERIC BIO INCcall | $0 | – | -61,300 | -100.0% | -0.31% | – |
| RYTM | Exit | RHYTHM PHARMACEUTICALS INC | $0 | – | -65,000 | -100.0% | -0.45% | – |
| TCDA | Exit | TRICIDA INC | $0 | – | -200,000 | -100.0% | -0.59% | – |
| Exit | MOONLAKE IMMUNOTHERAPEUTICSclass a ord | $0 | – | -300,000 | -100.0% | -0.65% | – | |
| ITCI | Exit | INTRA-CELLULAR THERAPIES INC | $0 | – | -60,000 | -100.0% | -0.78% | – |
| HZNP | Exit | HORIZON THERAPEUTICS PUB L | $0 | – | -75,000 | -100.0% | -1.30% | – |
| RETA | Exit | REATA PHARMACEUTICALS INCcall | $0 | – | -200,000 | -100.0% | -1.41% | – |
| FOLD | Exit | AMICUS THERAPEUTICS INC | $0 | – | -500,000 | -100.0% | -1.46% | – |
| TCDA | Exit | TRICIDA INCcall | $0 | – | -500,000 | -100.0% | -1.47% | – |
| ALT | Exit | ALTIMMUNE INC | $0 | – | -435,000 | -100.0% | -1.56% | – |
| AXSM | Exit | AXSOME THERAPEUTICS INCcall | $0 | – | -150,000 | -100.0% | -1.88% | – |
| SGEN | Exit | SEAGEN INCcall | $0 | – | -50,000 | -100.0% | -1.92% | – |
| Exit | AMYLYX PHARMACEUTICALS INCput | $0 | – | -500,000 | -100.0% | -3.95% | – | |
| Exit | DICE THERAPEUTICS INCcall | $0 | – | -700,000 | -100.0% | -3.98% | – | |
| RLMD | Exit | RELMADA THERAPEUTICS INC | $0 | – | -425,000 | -100.0% | -4.42% | – |
| RLMD | Exit | RELMADA THERAPEUTICS INCput | $0 | – | -500,000 | -100.0% | -5.20% | – |
| XBI | Exit | SPDR SER TRput | $0 | – | -500,000 | -100.0% | -11.13% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MIRATI THERAPEUTICS INC | 30 | Q3 2023 | 7.3% |
| ASCENDIS PHARMA A/S - ADR | 28 | Q3 2023 | 11.8% |
| BIOCRYST PHARMACEUTICALS INC | 25 | Q2 2023 | 2.4% |
| AMICUS THERAPEUTICS INC | 23 | Q3 2023 | 5.6% |
| SAREPTA THERAPEUTICS INC | 22 | Q3 2023 | 9.1% |
| SPDR SER TR | 20 | Q3 2022 | 16.9% |
| IOVANCE BIOTHERAPEUTICS INC | 18 | Q2 2023 | 5.5% |
| ROCKET PHARMACEUTICALS INC | 18 | Q2 2023 | 6.1% |
| SAGE THERAPEUTICS INC | 18 | Q1 2021 | 4.8% |
| IMMUNOMEDICS INC | 17 | Q2 2020 | 8.7% |
View Ghost Tree Capital, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-16 |
| 13F-HR | 2021-11-15 |
View Ghost Tree Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.